131 related articles for article (PubMed ID: 19604036)
1. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
3. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
[TBL] [Abstract][Full Text] [Related]
5. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Sekino K; Kubota T; Okada Y; Yamada Y; Yamamoto K; Horiuchi R; Kimura K; Iga T
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):589-92. PubMed ID: 14504849
[TBL] [Abstract][Full Text] [Related]
6. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
[TBL] [Abstract][Full Text] [Related]
7. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
Williamson KM; Patterson JH; McQueen RH; Adams KF; Pieper JA
Clin Pharmacol Ther; 1998 Mar; 63(3):316-23. PubMed ID: 9542475
[TBL] [Abstract][Full Text] [Related]
8. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.
Zaidenstein R; Soback S; Gips M; Avni B; Dishi V; Weissgarten Y; Golik A; Scapa E
Ther Drug Monit; 2001 Aug; 23(4):369-73. PubMed ID: 11477318
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
Kazierad DJ; Martin DE; Blum RA; Tenero DM; Ilson B; Boike SC; Etheredge R; Jorkasky DK
Clin Pharmacol Ther; 1997 Oct; 62(4):417-25. PubMed ID: 9357393
[TBL] [Abstract][Full Text] [Related]
13. Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers.
Wang G; Xiao CQ; Li Z; Guo D; Chen Y; Fan L; Qian RH; Peng XJ; Hu DL; Zhou HH
Ann Pharmacother; 2009 Jun; 43(6):1045-9. PubMed ID: 19458107
[TBL] [Abstract][Full Text] [Related]
14. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.
Yang SH; Cho YA; Choi JS
Acta Pharmacol Sin; 2011 Jul; 32(7):967-72. PubMed ID: 21666702
[TBL] [Abstract][Full Text] [Related]
15. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
[TBL] [Abstract][Full Text] [Related]
16. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
17. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Allabi AC; Gala JL; Horsmans Y; Babaoglu MO; Bozkurt A; Heusterspreute M; Yasar U
Clin Pharmacol Ther; 2004 Aug; 76(2):113-8. PubMed ID: 15289788
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
19. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
Stearns RA; Chakravarty PK; Chen R; Chiu SH
Drug Metab Dispos; 1995 Feb; 23(2):207-15. PubMed ID: 7736913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
